Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study
Ramón García‐Sánz, Roger G. Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen O. McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cohen, Constantine S. Tam (2025). Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. , 9(24), DOI: https://doi.org/10.1182/bloodadvances.2024015596.
Article39 days agoBiomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen O. McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Meletios A Dimopoulos (2024). Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia. , 8(7), DOI: https://doi.org/10.1182/bloodadvances.2023010906.
Article39 days agoZanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Sheel Patel, Aileen Cohen, Constantine S. Tam (2023). Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. , 41(33), DOI: https://doi.org/10.1200/jco.22.02830.
Article39 days agoZanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Sheel Patel, Aileen Cohen, Constantine S. Tam (2023). Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. , 41(33), DOI: https://doi.org/10.1200/jco.22.02830.
Article39 days agoClinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib
Ramón García‐Sánz, Roger G. Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen O. McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam (2023). Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib. , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-174294.
Article39 days ago